کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9267794 | 1218792 | 2005 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
BAFF is elevated in serum of patients with Wegener's granulomatosis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TNFB-cell activating factor of the TNF familyPR3ACRPANCA - BENCHMPO - DFORheumatoid arthritis - آرتریتروماتوئیدAutoantibody - اتوآنتی بادیHuman - انسانBAFF - بافEnzyme-linked immunosorbent assay - تست الیزاELISA - تست الیزاSerum - سرمtumour necrosis factor - عامل نکروز تومورSystemic lupus erythematosus - لوپوس اریتماتوی سیستمیکSLE - لوپوس منتشر یا لوپوس اریتماتوس سیستمیکmyeloperoxidase - میلوپراکسیداز C-reactive protein - پروتئین واکنشی سیCRP - پروتئین واکنشی سی یا سی. آر. پی proteinase 3 - پروتئیناز 3American College of Rheumatology - کالج آمریکایی روماتولوژیCanca - کانکاWegener's granulomatosis - گرانولوماتوز Wegener
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
BAFF (B-cell activating factor of the TNF family) plays a crucial role in B-cell survival. Elevated BAFF serum levels have been linked to several autoimmune diseases in humans, and therapies targeting BAFF were successful in animal models of rheumatoid arthritis and systemic lupus erythematosus. Wagener's granulomatosis (WG), a chronic systemic vasculitis, is characterized by circulating autoantibodies (cANCA) targeting neutrophils, which can produce BAFF. To investigate whether BAFF is involved in WG pathology, BAFF serum levels were measured by ELISA in 46 WG patients and 62 healthy donors. We report the novel finding that in WG patients serum levels of BAFF were significantly increased (median 3.95 ng/ml, p = 0.009) compared to healthy controls (median 2.38 ng/ml). The difference was even more pronounced when comparing controls with untreated WG patients (median 4.61 ng/ml, p = 0.001). Treatment of WG patients with glucocorticoids was associated with lower BAFF levels. The serum BAFF level in treated WG patients was about the same as in the control group. We propose that BAFF might be a pathogenic factor in WG and that targeting BAFF may represent a new therapeutic strategy in a subset of chronically relapsing WG patients with elevated BAFF levels.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Autoimmunity - Volume 25, Issue 4, December 2005, Pages 298-302
Journal: Journal of Autoimmunity - Volume 25, Issue 4, December 2005, Pages 298-302
نویسندگان
Markus Krumbholz, Ulrich Specks, Manfred Wick, Susan L. Kalled, Dieter Jenne, Edgar Meinl,